WHAT IS CLAIMED IS:

1. Use of plinabulin, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in combination with one or more G-CSF drug for the treatment of docetaxel-induced neutropenia, wherein the plinabulin is to be administered as a single dose of plinabulin in a 21-day docetaxel treatment cycle.

2. Use of plinabulin, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in combination with one or more G-CSF drug for the treatment of docetaxel-induced neutropenia, wherein the plinabulin is to be administered as a single dose in a 21-day docetaxel treatment cycle less than 2 hours after the administration of docetaxel.

3. The use of claim 1 or 2, wherein the amount of plinabulin in the single dose is greater than 1 mg/m^2 and less than 40 mg/m^2.

4. Use of plinabulin, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in combination with one or more G-CSF drug for the treatment of docetaxel-induced neutropenia, wherein the plinabulin is to be administered as a single dose in a 21-day docetaxel treatment cycle less than 20 mg/m^2.

5. Use of plinabulin, for a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in combination with one or more G-CSF drug for the treatment of docetaxel-induced neutropenia, wherein the plinabulin is to be administered as a single dose of plinabulin in a 21-day docetaxel treatment cycle, wherein the amount of plinabulin to be administered is less than 30 mg/m^2 per treatment cycle.

6. The use of any one of claims 1 to 5, wherein the plinabulin is to be administered less than 1 hour after the administration of docetaxel.

7. The use of any one of claims 1 to 5, wherein the plinabulin is to be administered about 30 mins after the administration of docetaxel.

8. Use of plinabulin, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) or Docetaxel and Cyclophosphamide (TC) chemotherapy-induced neutropenia, wherein the plinabulin is to be administered as a single dose in a 21-day treatment cycle.

9. Use of plinabulin, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) or Docetaxel and Cyclophosphamide (TC) chemotherapy-induced neutropenia, wherein the plinabulin is to be administered less than 2 hours after the administration of the TAC or TC chemotherapy.

10. The use of claim 8 or 9, wherein the amount of plinabulin is greater than 1 mg/m^2 and less than 40 mg/m^2.

11. Use of plinabulin, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) or Docetaxel and Cyclophosphamide (TC) chemotherapy-induced neutropenia, wherein the plinabulin is to be administered at a dose less than 20 mg/m^2.

12. Use of plinabulin, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) or Docetaxel and Cyclophosphamide (TC) chemotherapy-induced neutropenia, wherein the plinabulin is to be administered as a single dose of plinabulin in a 21- day treatment cycle, wherein the amount of plinabulin to be administered is less than 30 mg/m^2 per treatment cycle.

13. The use of any one of claims 8-12, wherein the plinabulin is to be administered less than 1 hour after the administration of the TAC or TC chemotherapy

14. The use of any one of claims 8-13, wherein the plinabulin is to be administered about 30 mins after the administration of the TAC or TC chemotherapy.

15. The use of any one of claims 1-13, wherein the neutropenia is a grade 3 or 4 neutropenia.

16. The use of any one of claims 1-15, wherein the neutropenia is a grade 4 neutropenia.

17. The use of any one of claims 1-16, comprising reducing an incidence of grade 4 neutropenia by at least 5%.

18. The use of any one of claims 1-17, further comprising reducing a duration of grade 4 neutropenia by at least about 2 times.

19. The use of any one of claims 1-18, in the manufacture of a medicament for a treatment of a medical condition further comprising treatment of a cancer, wherein the cancer is selected from advanced or metastatic breast cancer, early breast cancer, non-small cell lung cancer, or refractory metastatic prostate cancer.